Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theriva BiologicsTOVX 26 EV-to-EBITDA is 0.01 as of Aug. 14, 2026, which is 50% below its 10-year median of 0.02. GuruFocus rates TOVX with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 400 Biotechnology companies, Theriva Biologics ranks better than 98% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Theriva Biologics's enterprise value is $-0.18 Mil.
Theriva Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-21.66 Mil. Therefore, Theriva Biologics's EV-to-EBITDA for today is 0.01.
The historical rank and industry rank for Theriva Biologics's EV-to-EBITDA or its related term are showing as below:
TOVX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.24 Med: 0.02 Max: 0.1
Current: 0.01
During the past 13 years, the highest EV-to-EBITDA of Theriva Biologics was 0.10. The lowest was -0.24. And the median was 0.02.
TOVX's EV-to-EBITDA is ranked better than 98% of 400
companies
in the Biotechnology industry
Industry Median: 13.485
vs TOVX: 0.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Theriva Biologics's PE Ratio (TTM) for today is calculated as:
Theriva Biologics's share price for today is $0.23.
Theriva Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.528.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Theriva Biologics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theriva Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theriva Biologics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theriva Biologics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Theriva Biologics's EV-to-EBITDA falls into.
Theriva Biologics's current Enterprise Value is $-0.18 Mil.
Theriva Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theriva Biologics (TOVX) has a EV-to-EBITDA of 0.01 as of Aug. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Theriva Biologics. This is 50% below median its historical median of 0.02. According to the industry distribution chart, Theriva Biologics ranks #8 out of 400 companies in the Biotechnology industry, placing it in the top 2%.
Is Theriva Biologics' EV-to-EBITDA too high?
Theriva Biologics' current EV-to-EBITDA of 0.01 is 50% below median its 10-year median of 0.02. The Biotechnology industry median EV-to-EBITDA is 13.49. Theriva Biologics' value of 0.01 is 99.9% below this industry median. Based on the distribution chart, Theriva Biologics ranks #8 out of 400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Theriva Biologics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' EV-to-EBITDA compare to BIVI and BCLI?
According to the Biotechnology industry distribution chart, Theriva Biologics ranks #8 out of 400 companies for EV-to-EBITDA. This places Theriva Biologics in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.49. Theriva Biologics' value of 0.01 is 99.9% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 13.49, Theriva Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.49, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theriva Biologics's current EV-to-EBITDA of 0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Theriva Biologics. For the Biotechnology industry, the median EV-to-EBITDA is 13.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theriva Biologics's current EV-to-EBITDA is 0.01, which is 50% below median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (TOVX) has a current EV-to-EBITDA of 0.01. The current EV-to-EBITDA is 0.01, which is 50% below median its 10-year median of 0.02 and 99.9% below the Biotechnology industry median of 13.49. Theriva Biologics' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Theriva Biologics (TOVX), the current EV-to-EBITDA is 0.01 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
26GF Score
Get the complete analysis for TOVX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOVX has been successfully added to your 
